Literature DB >> 24448475

Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing.

H-J Guchelaar1, H Gelderblom2, T van der Straaten1, J H M Schellens3, J J Swen1.   

Abstract

Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24448475     DOI: 10.1038/clpt.2014.13

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Genomic analysis in the clinic: benefits and challenges for health care professionals and patients in Brazil.

Authors:  Patrícia Ashton-Prolla; José Roberto Goldim; Filippo Pinto E Vairo; Ursula da Silveira Matte; Jorge Sequeiros
Journal:  J Community Genet       Date:  2015-06-04

Review 2.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

3.  What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Authors:  Meta H Diekstra; Xiaoyan Liu; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Pharmacogenomics       Date:  2016-12-14       Impact factor: 2.533

Review 4.  Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.

Authors:  Elisa Pezzolo; Yasmina Modena; Barbara Corso; Pietro Giusti; Milena Gusella
Journal:  Eur J Clin Pharmacol       Date:  2015-03-06       Impact factor: 2.953

5.  Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.

Authors:  Annamaria Ruzzo; Francesco Graziano; Fabio Galli; Elisa Giacomini; Irene Floriani; Francesca Galli; Eliana Rulli; Sara Lonardi; Monica Ronzoni; Bruno Massidda; Vittorina Zagonel; Nicoletta Pella; Claudia Mucciarini; Roberto Labianca; Maria Teresa Ionta; Enzo Veltri; Pietro Sozzi; Sandro Barni; Vincenzo Ricci; Luisa Foltran; Mario Nicolini; Edoardo Biondi; Annalisa Bramati; Daniele Turci; Silvia Lazzarelli; Claudio Verusio; Francesca Bergamo; Alberto Sobrero; Luciano Frontini; Mauro Magnani
Journal:  Sci Rep       Date:  2014-11-05       Impact factor: 4.379

6.  A Pilot Study on the Whole Exome Sequencing of Prostate Cancer in the Indian Phenotype Reveals Distinct Polymorphisms.

Authors:  Ayam Gupta; Nidhi Shukla; Mamta Nehra; Sonal Gupta; Babita Malik; Ashwani Kumar Mishra; Maneesh Vijay; Jyotsna Batra; Nirmal Kumar Lohiya; Devendra Sharma; Prashanth Suravajhala
Journal:  Front Genet       Date:  2020-08-25       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.